A platform extensible beyond COVID-19, I.e. Potential integration with existing vaccine portfolios Opportunity for early partnership or acquisition the breaking through technology for respiratory pathogens Blocking infection at the point of entry — with scalable, needle-free immunity.
Developing next-generation vaccines delivery platform, designed for mucosal and systemic protection. Current vaccines fall short where it matters most: Limited protection against infection and transmission Waning immunity requiring repeated boosters Injection-based delivery limiting scalability Cold-chain dependence restricting global access Result: The world remains underprepared for respiratory pandemics.
Our Approach Biotav Shield is developing a platform for orally delivered live attenuated vaccines, designed to activate immunity where infection begins. Oral delivery via enteric capsule Induction of mucosal (IgA) and systemic immunity Designed for durable protection and transmission reduction Dr. Yair Saar, DVM Founder & Chief Executive Officer Dr. Yair Saar is the Founder and Chief Executive Officer of Biotav Shield Ltd, where he leads the company’s mission to deliver scientific breakthroughs that can transform patient health.
His leadership focuses on advancing innovative technologies, accelerating drug development, and building a science-driven organization dedicated to improving global healthcare. With more than 30 years of experience in vaccinology and biotechnology, Dr. Saar has led international collaborations and business development across multiple markets, including China and Austria.
His global perspective has strengthened his understanding of healthcare systems, patient needs, and the importance of innovation in modern medicine.